

## Global Myelodysplastic Syndrome Drugs Market Size, Share And Growth Analysis For 2024-2033

The Business Research Company's Myelodysplastic Syndrome Drugs Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

LONDON, GREATER LONDON, UK, August 13, 2024 /EINPresswire.com/ --The <u>myelodysplastic syndrome drugs</u> market has experienced robust growth in recent years, expanding from \$2.07 billion in 2023 to \$2.28 billion in 2024



at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to aging population, advancements in diagnostics, chemotherapy-related MDS cases, increased cancer survivors, clinical research and drug development.

"

You Can Now Pre Order Your Report To Get A Swift Deliver With All Your Needs" The Bussiness Research Company Strong Future Growth Anticipated

The myelodysplastic syndrome drugs market is projected to continue its strong growth, reaching \$3.26 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to growing geriatric population, advancements in targeted therapies, increased understanding of disease mechanisms, rising awareness and early diagnosis, expansion of oncology

research.

Explore Comprehensive Insights Into The Global Myelodysplastic Syndrome Drugs Market With A Detailed Sample Report:

https://www.thebusinessresearchcompany.com/sample\_request?id=10675&type=smp

Growth Driver Of The Myelodysplastic Syndrome Drugs Market The increase in the incidence of myelodysplastic syndrome is expected to propel the growth of the myelodysplastic syndrome drug market over the coming years. Myelodysplastic syndrome (MDS) is a group of disorders characterized by abnormal development and maturation of blood cells in the bone marrow. It is a type of blood cancer that primarily affects the production of healthy blood cells. Myelodysplastic syndrome drugs are used in treating myelodysplastic syndrome and involve medications to inhibit or modulate the immune system to lessen the requirement for red blood cell transfusions.

Explore The Report Store To Make A Direct Purchase Of The Report: <u>https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-</u> <u>market-report</u>

## Major Players And Market Trends

Key players in the myelodysplastic syndrome drugs market include Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited.

Major companies operating in the myelodysplastic syndrome drugs market are increasing their focus on introducing novel drugs, such as TIBSOVO, to gain a competitive edge in the market. TIBSOVO is an oral targeted therapy that inhibits the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. It is approved for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS).

## Segments:

 By Therapeutic Class: Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics
By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts

- 3) By Route of Administration: Oral, Parenteral
- 4) By Applications: Original, Generics
- 5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers

Geographical Insights: North America Leading The Market

North America was the largest region in the Myelodysplastic syndrome drugs market in 2023. Asia-Pacific is expected to be the fastest growing region in the global myelodysplastic syndrome drugs market report during the forecast period. The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Myelodysplastic Syndrome Drugs Market Definition

Myelodysplastic syndrome (MDS) is a diverse set of illnesses in which the bone marrow fails to create enough healthy blood cells (red blood cells, white blood cells, and platelets) due to aberrant cell formation and maturation. This condition is caused by uncontrolled cell growth and division that damages tissue. Myelodysplastic syndrome drugs include epoetin alfa, darbepoetin alfa, filgrastim, and other MDS drugs.

Myelodysplastic Syndrome Drugs Global Market Report 2024 from The Business Research

Company covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Myelodysplastic Syndrome Drugs Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on myelodysplastic syndrome drugs market size, myelodysplastic syndrome drugs market drivers and trends, myelodysplastic syndrome drugs market major players, myelodysplastic syndrome drugs competitors' revenues, myelodysplastic syndrome drugs market positioning, and myelodysplastic syndrome drugs market growth across geographies. The myelodysplastic syndrome drugs market report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company: Aircraft Actuator Global Market Report 2024 <u>https://www.thebusinessresearchcompany.com/report/aircraft-actuator-global-market-report</u>

Metabolic Disorders Drugs Global Market Report 2022 <u>https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-</u> <u>market-report</u>

Disposable Intestinal Wash Bags Global Market Report 2024 <u>https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-</u> <u>market-report</u>

About The Business Research Company?

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information The Business Research Company Europe: +44 207 1930 708 Asia: +91 8897263534 Americas: +1 315 623 0293

Oliver Guirdham The Business Research Company +44 20 7193 0708 email us here Visit us on social media: Facebook X LinkedIn YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/734840352

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.